ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ALKS Stock Price » ALKS Stock News

Alkermes Share News

 Alkermes (mm) Stock Price
ALKS Stock Price
 Alkermes (mm) Stock Chart
ALKS Stock Chart
 Alkermes (mm) Stock News
ALKS Stock News
 Alkermes (mm) Company Information
ALKS Company Information
 Alkermes (mm) Stock Trades
ALKS Stock Trades

Eli Lilly Type-1 Diabetes Drug Fails Trial Efficacy Endpoint

DOW JONES NEWSWIRES Eli Lilly & Co. (LLY) and its partner in licensing diabetes-drug candidate teplizumab said the treatment failed to reach the main efficacy goal a late-stage study. As a results, Lilly and MacroGenics Inc. suspended further enrollment and dosing of patients in two other ongoing clinical trials of the treatment effect in type-1 diabetes. Teplizumab, which the companies license from PDL BioPharma Inc. (PDLI), was being tested to treat newly diagnosed type-1 diabetes, the less-common type of the disease. The treatment was meant to slow its progression. Gwen Krivi, a Lilly executive in diabetes product development, called the drug's failure to reach the primary endpoint "obviously disappointing. She said the two companies will be considering all options for teplizumab. Under the licensing arrangement, Lilly agreed to pay PDL BioPharma fees during testing of teplizumab and would pay royalties on sales if the drug is approved. The trial results follow other another disappointment for Lilly on a diabetes drug-candidate earlier this week. The Food and Drug Administration held off on approving the company's long-acting version of diabetes drug Byetta, requesting more testing and data analysis. Eli Lilly is developing the drug with Amylin Pharmaceuticals Inc. and Alkermes Inc. (ALKS). The approval was widely expected. Lilly shares were down 0.2% at $35.95 in after-hours trading, while PDL closed the regular session Wednesday up 2.2% at $5.59 and wasn't active after the close. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291;

Stock News for Alkermes (ALKS)
10/26/201616:00:00Alkermes to Host Conference Call to Discuss Third Quarter 2016...
10/21/201609:39:00U.S. Hot Stocks: Hot Stocks to Watch
10/20/201617:40:00Alkermes Shares Surge
10/20/201616:03:32Current Report Filing (8-k)
10/20/201616:00:00Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal...
10/13/201616:51:21Current Report Filing (8-k)
10/07/201616:04:28Statement of Changes in Beneficial Ownership (4)
10/04/201617:26:10Statement of Changes in Beneficial Ownership (4)
10/03/201607:00:00Alkermes Announces Initiation of Clinical Study Evaluating Metabolic...
09/22/201617:02:56Statement of Changes in Beneficial Ownership (4)
09/20/201616:14:42Amended Current Report Filing (8-k/a)
09/19/201617:23:00Statement of Changes in Beneficial Ownership (4)
09/19/201616:00:00Alkermes Announces Webcast of Analyst and Investor Event on September...
09/15/201617:05:11Statement of Changes in Beneficial Ownership (4)
09/12/201607:00:00Alkermes Launches Competitive Grants Program to Support People...
09/07/201617:32:47Statement of Changes in Beneficial Ownership (4)
09/07/201617:28:52Statement of Changes in Beneficial Ownership (4)
09/07/201617:17:33Statement of Changes in Beneficial Ownership (4)
09/07/201617:14:57Statement of Changes in Beneficial Ownership (4)
09/06/201616:00:00Alkermes’ Corporate Presentation to be Webcast at the Morgan S...

Alkermes and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations